Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$47.64 USD
+17.46 (57.85%)
Updated Sep 9, 2025 04:00 PM ET
After-Market: $47.63 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TRML 47.64 +17.46(57.85%)
Will TRML be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRML
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital